Balance Sheet
Cash Flow Statement
AmortizationAmortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Gains from Investment Securities (2024)

Historic Gains from Investment Securities for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$1.1 million.

  • BioLineRx's Gains from Investment Securities fell 5706.37% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.9 million, marking a year-over-year increase of 2147.32%. This contributed to the annual value of -$19.0 million for FY2024, which is 27156.69% down from last year.
  • According to the latest figures from Q3 2025, BioLineRx's Gains from Investment Securities is -$1.1 million, which was down 5706.37% from $1.9 million recorded in Q2 2025.
  • Over the past 5 years, BioLineRx's Gains from Investment Securities peaked at $7.8 million during Q2 2023, and registered a low of -$8.4 million during Q2 2024.
  • Moreover, its 3-year median value for Gains from Investment Securities was -$1.1 million (2025), whereas its average is -$1.4 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 24618.42% in 2024, then surged by 12262.83% in 2025.
  • BioLineRx's Gains from Investment Securities (Quarter) stood at -$2.9 million in 2023, then tumbled by 85.24% to -$5.4 million in 2024, then surged by 78.99% to -$1.1 million in 2025.
  • Its last three reported values are -$1.1 million in Q3 2025, $1.9 million for Q2 2025, and -$8.3 million during Q1 2025.